Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
TG Therapeutics, Inc.
Study ID
NCT07680946
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Ublituximab — DRUG
    Administered as an IV infusion.

Study Details

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Key Dates

First listed
Jul 2, 2026
Start date
Jul 3, 2026
Status verified
Jul 2026
Primary completion
Dec 1, 2028
Completion
Mar 1, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ublituximab
    Participants will receive ublituximab intravenous (IV) infusion.

Primary Outcome Measure

Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total Score [ Time Frame: At Week 12 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
TG Therapeutics Investigational Trial SiteLittle RockArkansas72204-
TG Therapeutics Investigational Trial SiteRichardsonTexas75080-

Find similar trials in Little Rock, AR

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
TG Therapeutics Investigational Trial Site· Little Rock, ARTG Therapeutics Investigational Trial Site· Richardson, TX

Related Studies